ArticleTherapeutic advances in medical oncology2021

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study).

Sung-Bae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.